Breakthrough Psoriasis in Patients Receiving Biologicals.

IF 5.2 Q1 DERMATOLOGY Psoriasis (Auckland, N.Z.) Pub Date : 2025-01-03 eCollection Date: 2025-01-01 DOI:10.2147/PTT.S502382
Thomas Damsin, Gilles Absil, Florence Libon, Nazli Tassoudji, Arjen F Nikkels
{"title":"Breakthrough Psoriasis in Patients Receiving Biologicals.","authors":"Thomas Damsin, Gilles Absil, Florence Libon, Nazli Tassoudji, Arjen F Nikkels","doi":"10.2147/PTT.S502382","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Biological therapies, including TNF-alpha, IL12/23, IL17 and IL23 antagonists, adequately control a very high number of patients with moderate-to-severe psoriasis with an excellent long-term safety profile. However, on occasion, patients on biological therapy with stabilized disease or complete remission report episodes of sudden breakthrough psoriasis.</p><p><strong>Aim: </strong>To study prospectively in a monocentric tertiary setting, the clinical characteristics of patients presenting a sudden breakthrough psoriasis although completely stabilized (PASI 90-100) under biological therapy.</p><p><strong>Materials and methods: </strong>Psoriasis patients treated by biological therapies achieving PASI 90-100 and with stabilized disease for at least 6 months were invited to enter the follow-up study for 5 years. The clinical features of patients presenting a breakthrough psoriasis were described as well as the rescue therapies and outcomes.</p><p><strong>Results: </strong>From the total cohort of 1121 patients with psoriasis receiving biologicals, 985 patients responded to the inclusion criteria. After 5 years, 10/882 cases (1,13%) of breakthrough psoriasis were identified. Two cases were induced by the Köbner phenomenon and 8 cases by severe psychological stress. Rescue therapies included topical very potent corticosteroids or additional injections of the biological. Two patients recovered spontaneously when the stressful event was resolved. In none of the cases, there was a consistency between the breakthrough event and the next scheduled injection, nor the duration of the exposure to the treatment. No biological class or agent could be systematically incriminated.</p><p><strong>Conclusion: </strong>Breakthrough psoriasis is an exceptional event among patients with stabilized psoriasis using biologicals, either triggered by the Köbner phenomenon or by severe psychological stress. The pathogenesis of the breakthrough events could be linked to stress- or Köbner-related immunomodulation, permitting breakthrough psoriasis lesions to appear.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"1-8"},"PeriodicalIF":5.2000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705962/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psoriasis (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PTT.S502382","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Biological therapies, including TNF-alpha, IL12/23, IL17 and IL23 antagonists, adequately control a very high number of patients with moderate-to-severe psoriasis with an excellent long-term safety profile. However, on occasion, patients on biological therapy with stabilized disease or complete remission report episodes of sudden breakthrough psoriasis.

Aim: To study prospectively in a monocentric tertiary setting, the clinical characteristics of patients presenting a sudden breakthrough psoriasis although completely stabilized (PASI 90-100) under biological therapy.

Materials and methods: Psoriasis patients treated by biological therapies achieving PASI 90-100 and with stabilized disease for at least 6 months were invited to enter the follow-up study for 5 years. The clinical features of patients presenting a breakthrough psoriasis were described as well as the rescue therapies and outcomes.

Results: From the total cohort of 1121 patients with psoriasis receiving biologicals, 985 patients responded to the inclusion criteria. After 5 years, 10/882 cases (1,13%) of breakthrough psoriasis were identified. Two cases were induced by the Köbner phenomenon and 8 cases by severe psychological stress. Rescue therapies included topical very potent corticosteroids or additional injections of the biological. Two patients recovered spontaneously when the stressful event was resolved. In none of the cases, there was a consistency between the breakthrough event and the next scheduled injection, nor the duration of the exposure to the treatment. No biological class or agent could be systematically incriminated.

Conclusion: Breakthrough psoriasis is an exceptional event among patients with stabilized psoriasis using biologicals, either triggered by the Köbner phenomenon or by severe psychological stress. The pathogenesis of the breakthrough events could be linked to stress- or Köbner-related immunomodulation, permitting breakthrough psoriasis lesions to appear.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
银屑病患者接受生物制剂治疗取得突破性进展。
背景:生物疗法,包括tnf - α、il - 12/23、il - 17和il - 23拮抗剂,能够充分控制大量中重度牛皮癣患者,并具有良好的长期安全性。然而,偶尔,疾病稳定或完全缓解的患者在生物治疗中报告突发突破性牛皮癣发作。目的:前瞻性研究单中心三级环境下突发性突破型银屑病患者在生物治疗下完全稳定(PASI 90-100)的临床特征。材料与方法:邀请PASI达到90-100且病情稳定至少6个月的银屑病生物治疗患者进入5年的随访研究。本文描述了突破性银屑病患者的临床特点,以及抢救治疗和结果。结果:在接受生物制剂治疗的1121例牛皮癣患者中,985例患者符合纳入标准。5年后确诊突破型银屑病10/882例(1.13%)。2例为Köbner现象所致,8例为严重心理应激所致。抢救治疗包括局部强力皮质类固醇或额外的生物注射。两名患者在应激事件解决后自行康复。在所有病例中,突破事件与下一次预定注射之间没有一致性,也没有暴露于治疗的持续时间。没有任何一类生物或生物制剂可以被系统地定罪。结论:突破性银屑病在使用生物制剂的稳定型银屑病患者中是一种罕见的事件,可能是由Köbner现象或严重的心理压力引起的。突破性事件的发病机制可能与压力或Köbner-related免疫调节有关,使突破性银屑病病变出现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
期刊最新文献
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report. Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients. Breakthrough Psoriasis in Patients Receiving Biologicals. Research Progress on Glycolysis Mechanism of Psoriasis. Unveiling Novel Protein Biomarkers for Psoriasis Through Integrated Analysis of Human Plasma Proteomics and Mendelian Randomization.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1